Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir®)<sup><sup><a href="#d33e371" rid="d33e371" class=" fn">☆</a></sup></sup>

Tatiana Kalinina

Dmitry Zlenko

Aleksei Kiselev

Alexander Litvin

Sergey Stovbun

^{V.V. Zakusov Institute of Pharmacology RAMS, Russia}

^{M.V. Lomonosov Moscow State University, Russia}

^{Federal Research and Clinical Center of Physical-Chemical Medicine FMBA, Russia}

^{N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, Moscow, Russia}

Dmitry V. Zlenko: moc.liamg@oknelzvd

^{Corresponding author.}moc.liamg@oknelzvd

Received 2020 May 1; Revised 2020 May 31; Accepted 2020 Jun 3.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Footnotes

^{The work was completed as a part of the state assignment (theme number AAAA-A20-120013190076-0).}

References

1. Stovbun S.V., Yakovenko L.VThe physicochemical basis of the biological activity and pharmacological properties of the antiviral agent Panavir. Mosc. Univ. Phys. Bull. 2014;69:542–547.[PubMed][Google Scholar]
2. Stovbun S., Berlin A., Mikhailov A., Sergienko V., Govorun V., Demina I., Kalinina TPhysicochemical properties of high-molecular-weight plant polysaccharide of hexose glycoside class (Panavir) with antiviral activity. Nanotechnologies in Russia. 2012;7:539–543.[PubMed][Google Scholar]
3. Martinez M.J.A., Olmo L.M.B.D., Benito P.BAntiviral activities of polysaccharides from natural sources. Stud. Nat. Prod. Chem. 2005;30:393–418.[PubMed][Google Scholar]
4. Wang W., Wang S.-X., Guan H.-SThe antiviral activities and mechanisms of marine polysaccharides: an overview. Marine Drugs. 2012;10:2795–2816.[Google Scholar]
5. Chen L., Huang GThe antiviral activity of polysaccharides and their derivatives. Int. J. Biol. Macromol. 2018;115:77–82.[PubMed][Google Scholar]
6. Melnikova S., Stovbun S., Korobkova E., Kiselev V., Kucherov VEfficacy of Panavir in patients with recurrent genital herpes. Russian Bulletin of Obstetrician-Gynecologist. 2017;13:97–101.[PubMed][Google Scholar]
7. Kovchur P., Bakhlaev IEfficacy of Panavir in treatment of chronic papillomavirus infections of the cervix uteri. Bulletin MSRU. 2011;1:24–28.[PubMed][Google Scholar]
8. Perlamutrov Y., Chernovaa N., Stovbun S., Kucherov V., Bagaeva M., Safronov DPapillomavirus infection in sexually active women of reproductive age: possibilities of safe and effective therapy. Russian Bulletin of Obstetrician-Gynecologist. 2014;14:90–93.[PubMed][Google Scholar]
9. Prokudina E., Galegov G., Semenova N., Grigoryeva T., Kalinina T., Litvin A., Stovbun S., Sergienko VEffect of Panavir on influenza a virus reproduction. Antibiot. Chemother. 2006;51:7–10.[PubMed][Google Scholar]
10. Lepekhin A., Ratnikova L., Litvin A., Stovbun S., Sergienko VAn experience of using Panavir in therapy of tick-borne encephalitis. Infectious Deseases. 2007;5:41–46.[PubMed][Google Scholar]
11. Gribencha S., Litvin A., Kokhnovich M., Sergienko V., Stovbun S., Yakimchuk P., Bezmen VProtective activity of Panavir in experimental rabies infection. Antibiot. Chemother. 2009;54:31–36.[PubMed][Google Scholar]
12. Rakhmanina N., Terekhova Y., Tsibezov V., Verkhovsky O., Ulasov VEfficacy evaluation of the treatment with “Forvet” (drug) for the feline infectious peritonitis development prophylactics. Russian Veterinary Journal. 2015;2:38–41.[PubMed][Google Scholar]
13. Kolbukhina L., Nosik N., Merkulova L., Braginskii D., Lavrukhina L., Kalinina T., Stovbun S., Litvin A., Sergienko VTime course of leukocyte interferon induction after single and repeated application of Panavir. Cytokines and Inflammation. 2009;8:49–52.[PubMed][Google Scholar]
14. Stovbun S., Safronov D., Kucherov V., Farzaliev T., Chekameyeva VAnti-inflamatory Panavir effect in simulation experiments and clinical practice. Bulletin MSRU. 2011;3:82–85.[PubMed][Google Scholar]
15. Litvin A., Kalinina T., Sergienko V., Stovbun SComparative experimental study of specific anti-inflammatory activities and antipiretic properties of Panavir and Diclofenac in rats. Cytokines and Inflammation. 2012;11:123–127.[PubMed][Google Scholar]
16. Gautier J., Yann RA new symptom of COVID-19: loss of taste and smell. Obesity. 2020;28(5) 848–848. [Google Scholar]
17. A.E. Cha. Washington Post; 2020. Young and middle-aged people, barely sick with COVID-19, are dying of strokes. April 25, 2020. [PubMed]
18. Stovbun S., Safronov D., Farzaliev T., Nerobkova LInfluence of Panavir on electroencephalogram of human brain. Bulletin MSRU. 2011;2:94–101.[PubMed][Google Scholar]
19. Kalinina T., Nerobkova L., Voronina T., Stovbun S., Litvin A., Sergienko VStudy of antiparkinsonic activity of Panavir on a model of parkinson syndrome induced by systemic administration of MPTP to outbred rats and C57Bl/6 mice. Bull. Exp. Biol. Med. 2005;140:55–57.[PubMed][Google Scholar]